Mahi Biotech Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 09-12-2024
- Paid Up Capital ₹ 0.50 M
as on 09-12-2024
- Company Age 11 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Revenue %
(FY 2020)
- Profit 57.62%
(FY 2020)
- Ebitda 138.89%
(FY 2020)
- Net Worth -28.65%
(FY 2020)
- Total Assets -41.60%
(FY 2020)
About Mahi Biotech
The Corporate was formerly known as Mahi Biotech Private Limited. The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.50 M, as per Ministry of Corporate Affairs (MCA) records.
Sanjeev Shakya, Sunita Shakya, Neeraj Shakya, and Two other members serve as directors at the Company.
- CIN/LLPIN
U74120UP2013PLC058001
- Company No.
058001
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
27 Jun 2013
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Budaun, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Mahi Biotech Limited offer?
Mahi Biotech Limited offers a wide range of products and services, including Tea & Coffee, Herbal Tea, Ayurvedic,Herbal Products & Medicine, Ayurvedic Medicine, Common Disease Medicines, Pharmaceutical Tablets, Pain Relief Drugs & Pharmaceuticals, Arthritic Drugs, Ayurvedic & Herbal Health Supplement, Herbal Sexual Health Supplement.
Who are the key members and board of directors at Mahi Biotech?
Board Members(5)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Sanjeev Shakya  | Director | 27-Jun-2013 | Current |
| Sunita Shakya | Director | 27-Jun-2013 | Current |
| Neeraj Shakya | Director | 27-Jun-2013 | Current |
| Sony Singh | Director | 27-Jun-2013 | Current |
| Pooja Shakya | Director | 28-May-2016 | Current |
Financial Performance of Mahi Biotech.
Mahi Biotech Limited, for the financial year ended 2020, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 57.62% increase in profit. The company's net worth observed a substantial decline by a decrease of 28.65%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mahi Biotech?
In 2018, Mahi Biotech had a promoter holding of 94.00% and a public holding of 6.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Mahi Biotech?
Unlock and access historical data on people associated with Mahi Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mahi Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mahi Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
